home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9603.zip
/
M9630613.TXT
< prev
next >
Wrap
Text File
|
1996-02-27
|
3KB
|
46 lines
Document 0613
DOCN M9630613
TI SDZ PRI 053, an orally bioavailable human immunodeficiency virus type 1
proteinase inhibitor containing the 2-aminobenzylstatine moiety.
DT 9603
AU Billich A; Fricker G; Muller I; Donatsch P; Ettmayer P; Gstach H; Lehr
P; Peichl P; Scholz D; Rosenwirth B; Sandoz Research Institute, Vienna,
Austria.
SO Antimicrob Agents Chemother. 1995 Jul;39(7):1406-13. Unique Identifier :
AIDSLINE MED/96104872
AB A series of inhibitors of human immunodeficiency virus type 1 (HIV-1)
proteinase containing the 2-aralkyl-amino-substituted statine moiety as
a novel transition-state analog was synthesized, with the aim to obtain
compounds which combine anti-HIV potency with oral bioavailability. The
reduced-size 2-aminobenzylstatine derivative SDZ PRI 053, which contains
2-(S)-amino-3-(R)-hydroxyindane in place of an amino acid amide, is a
potent and orally bioavailable inhibitor of HIV-1 replication. The
antiviral activity of SDZ PRI 053 was demonstrated in various cell
lines, in primary lymphocytes, and in primary monocytes, against
laboratory strains as well as clinical HIV-1 isolates (50% effective
dose = 0.028 to 0.15 microM). Cell proliferation was impaired only at
100- to 300-fold-higher concentrations. The mechanism of antiviral
action of the proteinase inhibitor SDZ PRI 0.53 was demonstrated to be
inhibition of gag precursor protein processing. The finding that the
inhibitory potency of SDZ PRI 053 in chronic virus infection, determined
by p24 release, was considerably lower than that in de novo infection
may be explained by the fact that the virus particles produced in the
presence of SDZ PRI 053 are about 50-fold less infectious than those
from untreated cultures. Upon intravenous administration, half-lives in
blood of 100 and 32 min in mice and rats, respectively, were measured.
Oral bioavailability of SDZ PRI 053 in rodents was 20 to 60%, depending
on the dose.(ABSTRACT TRUNCATED AT 250 WORDS)
DE Administration, Oral Amino Acid Sequence Animal Biological
Availability Blood Proteins/METABOLISM Cell Line Comparative Study
Dogs Female Gene Products, gag/ANTAGONISTS & INHIB/METABOLISM Human
HIV Protease Inhibitors/CHEMICAL SYNTHESIS/*PHARMACOLOGY/
PHARMACOKINETICS HIV-1/DRUG EFFECTS/ENZYMOLOGY/PHYSIOLOGY
Indans/BLOOD/*PHARMACOLOGY/PHARMACOKINETICS Mice Mice, Inbred BALB C
Molecular Sequence Data Protein Binding Rats Rats, Wistar
Structure-Activity Relationship Virus Replication/DRUG EFFECTS JOURNAL
ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).